Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.
The potential of CAR T-cell therapy for the treatment of solid tumors was unlocked in a preclinical trial by researchers at St. Jude Children’s Research Hospital who discovered a molecular mechanism. The findings were released in the journal Nature.
Cedars-Sinai Cancer Center scientists found that cancerous tumors known as soft-tissue sarcomas generate a protein that changes immune cells from tumor attacking to tumor-promoting.
Researchers from Wake Forest University School of Medicine have discovered a possible new approach to treating solid tumors through the creation of a novel nanoparticle. Solid tumors are found in cancers such as breast, head and neck, and colon cancer.
The interferon-gamma receptor (IFNgR) signaling pathway has been identified to be crucial for the vulnerability of glioblastoma tumors to death by CAR T-cell immunotherapy, according to researchers at Massachusetts General Hospital (MGH).
Micronutrient deficits can increase inflammation and make the immune system more susceptible to allergens. Iron deficiency indicates danger to immune cells and causes an excessive immunological response.
Lung cancer affects approximately 48,500 persons in the United Kingdom every year. New treatments are urgently needed because only around 20% of patients live 5 years after diagnosis, and it is the leading cause of cancer death.
The University of Texas MD Anderson Cancer Center scientists have created an ultrasound-guided cancer immunotherapy approach that promotes systemic antitumor immunity and increases immune checkpoint blockade therapeutic potential. Nature Nanotechnology published the results of the pioneering study.
An international collaboration of scientists has discovered a new technique to kill cancers that are difficult to treat, according to an article published in Nature.
Glioblastomas (GBMs) are cancerous tumors of the brain and spinal cord that are incredibly aggressive.
Patients are more susceptible to fungal infections because the immune system in the gut is disrupted when patients are given antibiotics in the hospital.
Many cancers include genetic “hotspots,” or sections of DNA that are subject to mutation. For example, a mutation in the TP53 gene is found in more than 50% of all cancers, generally within a narrow DNA range.
Many cancer patients have benefited from the development of anti-cancer immunotherapy drugs known as immune checkpoint inhibitors, but patients with mucosal melanomas—melanomas that occur in the mucous membranes of the head, neck, eyes, respiratory system, and genitourinary region rather than on the skin—are highly resistive to immune checkpoint inhibitors for reasons researchers do not fully understand.
The dysfunction of memory CD8 + T cell can not be reverted by successful clearance of hepatitis C virus (HCV) after direct-acting antivirals (DAA) therapy, increasing the risk of reinfection with HCV.
A mutated gene found in more than 20% to 30% of breast cancer recurrences may help tumors become more aggressive and promote metastasis, according to a pair of new studies that uncover mechanisms behind these processes and point to new therapy targets.
Combining a retrospective analysis of clinical records with in-depth laboratory studies, researchers at The University of Texas MD Anderson Cancer Center have discovered that vitamin E can enhance immunotherapy responses by stimulating the activity of dendritic cells in the tumor.
Therapies based on engineered immune cells have recently emerged as a promising approach in the treatment of cancer.
Ovarian cancer is a difficult to diagnose malignancy that is often caught at a more advanced stage. Treatments for this cancer have changed little over the past few decades, with surgery and chemotherapy being the most common therapeutic approaches.
Chronic viral infections and cancers can damage the immune system permanently, diminishing the ability of immune killer T cells to destroy tumor cells or virus-infected cells—a condition known as “immune exhaustion.”
Chimeric antigen receptor (CAR) T cells can be remarkably effective in treating leukemias and lymphomas, but there are no successful immunotherapies for neuroendocrine tumors (NETs) and gastrointestinal cancers (GICs) yet.
Researchers have created a novel method that allows them to correlate particular genes to complex tumor properties at a size and resolution that has never been achievable.